Chalice Brands Ltd. banner
C

Chalice Brands Ltd.
OTC:CHALF

Watchlist Manager
Chalice Brands Ltd.
OTC:CHALF
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $2.9m

EV/S

0.8
Current
0%
Cheaper
vs 3-y average of 0.8

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.8
=
Enterprise Value
$34.3m
/
Revenue
$31.5m

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.8
=
Enterprise Value
$34.3m
/
Revenue
$31.5m

Valuation Scenarios

Chalice Brands Ltd. is trading below its 3-year average

If EV/S returns to its 3-Year Average (0.8), the stock would be worth $0 (0% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+267%
Average Upside
88%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 0.8 $0
0%
3-Year Average 0.8 $0
+0%
5-Year Average 0.8 $0
+1%
Industry Average 1.5 $0
+83%
Country Average 2.9 $0
+267%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
$34.3m
/
Oct 2021
$31.5m
=
0.8
Current
$34.3m
/
Dec 2021
$31.1m
=
1.1
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CA
Chalice Brands Ltd.
OTC:CHALF
19m USD 0.8 -1.3
US
Eli Lilly and Co
NYSE:LLY
820.3B USD 13.1 39.7
US
Johnson & Johnson
NYSE:JNJ
542.6B USD 5.9 25.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.7B GBP 5.2 27.8
CH
Novartis AG
SIX:NOVN
218.9B CHF 5.1 19.1
US
Merck & Co Inc
NYSE:MRK
272.8B USD 4.7 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4.1 11.4
US
Pfizer Inc
NYSE:PFE
152.3B USD 3.2 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
116.3B USD 3.1 16.5
P/E Multiple
Earnings Growth PEG
CA
C
Chalice Brands Ltd.
OTC:CHALF
Average P/E: 21.7
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
25.8
8%
3.2
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.8
25%
1.1
CH
Novartis AG
SIX:NOVN
19.1
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
16%
1

Market Distribution

Lower than 99% of companies in Canada
Percentile
1st
Based on 2 384 companies
1st percentile
0.3
Low
0 — 1.7
Typical Range
1.7 — 5.7
High
5.7 —
Distribution Statistics
Canada
Min 0
30th Percentile 1.7
Median 2.9
70th Percentile 5.7
Max 15 639 353.3

Chalice Brands Ltd.
Glance View

Market Cap
2.9m USD
Industry
Pharmaceuticals

Chalice Brands Ltd. is engaged in the development, processing, and distribution of medical cannabis products. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-10-14. The firm specializes in production, processing, wholesale, distribution and retail, with approximately 12 dispensaries owned and four dispensaries under management in Oregon. The firm is engaged in developing a dynamic portfolio built around the brands of Chalice Farms, with a focus on health and wellness. The firm's products include Private Stash distillate vaporizer cartridges and high dosage single serve Fruit Chew Blast product under both the Golden and Chalice brands. The firm also has a range of spectrum ethanol extract products under the RXO brand and a Live Resin and Distillate vaporizer cartridge under the Elysium Fields brand. The firm operates nationally through Fifth & Root and has operations in Oregon and California.

CHALF Intrinsic Value
Not Available
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett